Selective GH Stimulation Extensive Research One of Ipamorelin's most significant research advantages is its remarkable selectivity for growth hormone release without substantial effects on other pituitary hormones or stress hormones
Sign in to track orders, save addresses, and unlock member offers
Super-responders may see larger insulin excursions given their higher GH peaks
FDA's CJC-1295 evaluation explicitly separated CJC-1295 free base from CJC-1295 DAC free base and related salt forms
As always, we start every relationship with a thorough consultation to make sure glutathione IV therapy aligns with your specific health needs and goals
Safety Considerations and Contraindications Who Should Avoid CJC-1295 Ipamorelin Contraindications : Active cancer diagnosis (growth hormone can stimulate existing tumors) Pregnancy or breastfeeding Severe cardiovascular disease Uncontrolled diabetes Children and adolescents under 18 Potential Drug Interactions CJC-1295 Ipamorelin may interact with: Insulin and diabetes medications (can affect blood sugar) Corticosteroids (may blunt GH response) Thyroid medications (may require dose adjustments) Other hormone therapies Medical Supervision Requirements Consult healthcare providers before starting if you have: Diabetes or blood sugar issues Cardiovascular conditions History of cancer Current prescription medications Sleep disorders Our Clinics Experience with CJC-1295 Ipamorelin Dosing Through extensive clinical experience with CJC-1295 Ipamorelin protocols, weve observed optimal results with 200 mcg of each peptide administered before bed, 5 days per week
